PROFUND ADVISORS LLC - SAREPTA THERAPEUTICS INC ownership

SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 328 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.82 and the average weighting 0.2%.

Quarter-by-quarter ownership
PROFUND ADVISORS LLC ownership history of SAREPTA THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,477,672
+11.7%
12,190
+5.5%
0.08%
+15.5%
Q2 2023$1,322,935
+11.7%
11,552
+34.5%
0.07%
-2.7%
Q1 2023$1,184,235
-6.7%
8,592
-12.3%
0.07%
-11.0%
Q4 2022$1,268,847
+20.2%
9,792
+2.5%
0.08%
+7.9%
Q3 2022$1,056,000
+41.0%
9,549
-4.5%
0.08%
+58.3%
Q2 2022$749,000
-11.6%
9,998
-7.8%
0.05%
+33.3%
Q1 2022$847,000
-21.4%
10,848
-9.4%
0.04%
+2.9%
Q4 2021$1,078,000
-10.0%
11,975
-7.5%
0.04%
-12.5%
Q3 2021$1,198,000
+13.2%
12,950
-4.9%
0.04%
+11.1%
Q2 2021$1,058,000
+1.4%
13,615
-2.7%
0.04%
-10.0%
Q1 2021$1,043,000
-61.9%
13,992
-13.0%
0.04%
-66.7%
Q4 2020$2,741,000
+33.7%
16,080
+10.2%
0.12%
+14.3%
Q3 2020$2,050,000
-22.1%
14,596
-11.1%
0.10%
-28.6%
Q2 2020$2,633,000
+102.4%
16,419
+23.4%
0.15%
+50.0%
Q1 2020$1,301,000
-44.5%
13,304
-26.7%
0.10%
-3.9%
Q4 2019$2,343,000
+91.4%
18,158
+11.7%
0.10%
+64.5%
Q3 2019$1,224,000
-53.1%
16,253
-5.3%
0.06%
-50.0%
Q2 2019$2,609,000
+18.5%
17,171
-7.0%
0.12%
+17.0%
Q1 2019$2,201,000
+10.7%
18,466
+1.4%
0.11%
-13.8%
Q4 2018$1,988,000
-42.3%
18,218
-14.6%
0.12%
-6.1%
Q3 2018$3,447,00021,3430.13%
Other shareholders
SAREPTA THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
EcoR1 Capital, LLC 2,999,453$413,414,60713.31%
Casdin Capital, LLC 1,160,000$159,882,80013.17%
Ikarian Capital, LLC 271,300$37,393,2798.48%
Avoro Capital Advisors LLC 3,650,000$503,079,5007.46%
Evolutionary Tree Capital Management, LLC 36,190$4,988,0686.91%
Finepoint Capital LP 122,757$16,919,5976.46%
Ikarian Capital, LLC 205,400$28,310,2826.42%
Boxer Capital, LLC 775,000$106,8185.25%
Ghost Tree Capital, LLC 125,000$17,229,0005.09%
Logos Global Management LP 220,000$30,322,6004.34%
View complete list of SAREPTA THERAPEUTICS INC shareholders